Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III
暂无分享,去创建一个
A. Reuss | R. Wenham | A. Okamoto | S. Lheureux | K. Ushijima | O. Trédan | C. Aghajanian | N. Colombo | F. Heitz | P. Harter | C. Grimm | A. Chudecka-Głaz | E. Van Nieuwenhuysen | F. Trillsch | E. Day | M. Vardar | M. J. Rubio-Pérez | G. Nyvang | Giovanni Scambia | Jae-Weon Kim